Cancer in Greece

IARC estimates 63,549 new cancer cases and 31,965 cancer deaths in Greece in 2024; the commonest new cancers are breast, trachea, bronchus and lung and prostate. This page is assembled automatically from OnCo's data: 443 trials with a site there, 4 institutions, 1 company and 6 people, and says what OnCo does not yet hold.

Cancer figures, GLOBOCAN 2024

Compare countries →

New cases

63,549

all cancers

Deaths

31,965

all cancers

Incidence rate

273.4

per 100,000, age-standardised

Mortality rate

99.6

per 100,000, age-standardised

Cumulative risk

26.2%

of a cancer by age 74

Population

10,047,819

IARC, 2024

Built partly from other countries' data. IARC's method code for Greece's incidence estimate is 3b: national mortality estimates applied to model-based mortality-to-incidence ratios (neighbouring country registry data). Read the figures as a regional estimate, not a count.

Most new cases

Site	New cases	Rate	OnCo page
Breast	8,733	82.9	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Trachea, bronchus and lung	8,470	32.0	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Prostate	7,514	59.3	Prostate cancer
Colorectum	7,147	25.7	Colorectal cancer
Bladder	4,704	19.1	Bladder & urothelial cancer
Pancreas	2,204	7.4	Pancreatic ductal adenocarcinoma
Corpus uteri	1,992	18.7	Endometrial cancer
Leukaemia	1,899	8.6	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia
Stomach	1,880	6.6	Gastric & gastro-oesophageal junction cancer
Kidney	1,783	9.0	Renal cell carcinoma

Most deaths

Site	Deaths	Rate	OnCo page
Trachea, bronchus and lung	7,174	25.1	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Colorectum	3,503	9.3	Colorectal cancer
Breast	2,398	14.1	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Pancreas	2,053	6.5	Pancreatic ductal adenocarcinoma
Prostate	1,951	8.9	Prostate cancer
Liver and intrahepatic bile ducts	1,577	4.7	Hepatocellular carcinoma
Bladder	1,429	3.5	Bladder & urothelial cancer
Stomach	1,390	4.3	Gastric & gastro-oesophageal junction cancer
Leukaemia	1,329	4.0	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia
Brain, central nervous system	1,108	4.8	Glioma & glioblastoma

Incidence: method 3b, national mortality estimates applied to model-based mortality-to-incidence ratios (neighbouring country registry data).
Mortality: method 1, trends in national rates projected to 2024.
Rates are age-standardised per 100,000 (World standard population), both sexes, all ages. Non-melanoma skin cancer is left out of the site lists, as on the deep dives. IARC lists the country as “Greece”, in Southern Europe (Europe), Very High HDI, high income.
Source: Ervik M, Laversanne M, Lam F, Colombet M, Ferlay J, Filho AM, Bray F (2026). Global Cancer Observatory: Cancer Today (2024 estimates, version 1.0). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today, read through the IARC API on 2026-11-04.

Trials with a site here

443 trials in OnCo · 150 recruiting overall

443 trials

Trial			Lead sponsor
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis NCT04910685	Phase 2/3	Recruiting	Blueprint Medicines Corporation	88	2026-10-07
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) NCT07190248	Phase 3	Recruiting	Merck Sharp & Dohme LLC	219	2026-10-07
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) NCT07209111	Phase 2	Recruiting	Merck Sharp & Dohme LLC	72	2026-10-07
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) NCT06345729	Phase 3	Recruiting	Merck Sharp & Dohme LLC	241	2026-10-07
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer NCT06119581	Phase 3	Recruiting	Eli Lilly and Company	416	2026-10-07
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-34 NCT06731907	Phase 2	Recruiting	Merck Sharp & Dohme LLC	41	2026-10-07
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer NCT07525206	Phase 3	Recruiting	AbbVie	85	2026-10-07
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, NCT06820463	Phase 2	Recruiting	AbbVie	75	2026-10-07
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutati NCT07195695	Phase 3	Recruiting	Boehringer Ingelheim	202	2026-10-07
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pemb NCT03486873	Phase 3	Recruiting	Merck Sharp & Dohme LLC	782	2026-10-07
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) NCT07431827	Phase 3	Recruiting	Merck Sharp & Dohme LLC	112	2026-10-07
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML NCT07007312	Phase 3	Recruiting	Kura Oncology, Inc.	122	2026-10-07
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer NCT06890598	Phase 3	Recruiting	Eli Lilly and Company	366	2026-10-07
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) NCT06780098	Phase 2	Recruiting	Merck Sharp & Dohme LLC	46	2026-10-07
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) NCT07489495	Phase 3	Recruiting	Merck Sharp & Dohme LLC	99	2026-10-06
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) NCT06925737	Phase 3	Recruiting	Merck Sharp & Dohme LLC	298	2026-10-06
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) NCT07060807	Phase 3	Recruiting	Merck Sharp & Dohme LLC	200	2026-10-06
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc NCT07216703	Phase 3	Recruiting	Merck Sharp & Dohme LLC	180	2026-10-06
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) NCT06966700	Phase 3	Recruiting	Merck Sharp & Dohme LLC	326	2026-10-06
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) NCT07318558	Phase 3	Recruiting	Merck Sharp & Dohme LLC	165	2026-10-06
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) NCT07419295	Phase 3	Recruiting	Merck Sharp & Dohme LLC	104	2026-10-06
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Particip NCT06793215	Phase 3	Recruiting	Hoffmann-La Roche	288	2026-10-06
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) NCT06136650	Phase 3	Recruiting	Merck Sharp & Dohme LLC	330	2026-10-06
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) NCT06941272	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	64	2026-10-06
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) NCT06312176	Phase 3	Recruiting	Merck Sharp & Dohme LLC	259	2026-10-06
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) NCT06841354	Phase 3	Recruiting	Merck Sharp & Dohme LLC	281	2026-10-06
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participan NCT06952504	Phase 3	Recruiting	Merck Sharp & Dohme LLC	265	2026-10-06
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Pl NCT06824467	Phase 3	Recruiting	Merck Sharp & Dohme LLC	197	2026-10-06
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) NCT06393374	Phase 3	Recruiting	Merck Sharp & Dohme LLC	314	2026-10-06
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer NCT07166094	Phase 3	Recruiting	Genmab	177	2026-10-06

(showing the first 30)

Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Greece, captured 2026-10-07 to 2026-10-10. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Greece is open is on the registry page, under Contacts and Locations.

Institutions, companies and people

4 institutions

Hellenic Cancer Federation (ELLOK)Metaxa Cancer Hospital, Piraeus National and Kapodistrian University of Athens, School of Medicine Saint Savvas General Oncology Hospital of Athens

1 company

Hellenic Oncology Research Group

6 people

People whose main affiliation in OnCo is an institution or company in Greece.

Alexander J. Stratigos Christos Fasianos Georgios Kapetanakis Meletios A. Dimopoulos Panagiotis Klirides Sarantos Efstathopoulos

Approvals

Greece is an EU member state, so an EU centralised authorisation covers it: 309 products in OnCo carry a sourced EU row that is approved or conditional. See the approvals by region matrix. National procedures and reimbursement are not recorded.

From the country research ranking

Research funders: Hellenic Foundation for Research and Innovation.
Named in the ranking: Hellenic Cooperative Oncology Group.

From the country ranking's hand-curated row; follow its source before relying on a figure.

What OnCo does not yet hold

No registry figures. The figures above are IARC's estimates; OnCo has not read Greece's own cancer registry, its survival figures or its stage at diagnosis.
No payer detail: who pays for cancer care in Greece, what a patient pays, and which medicines are reimbursed.
No regulator detail: the national medicines agency's own procedures, beyond EU centralised authorisations.
No national cancer plan, guideline, screening schedule or treatment-centre list read from Greece's own sources.

A deep dive for Greece is ranked 28 of 60 in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.

Sources and machine-readable data

IARC Global Cancer Observatory, GLOBOCAN 2024: Cancer Today; Greece fact sheet.
ClinicalTrials.gov study records, courtesy of the US National Library of Medicine, as captured in each trial record.
OnCo records: each chip and card opens a record with its own sources.
This page as JSON: /api/v1/countries/gr.json; every country: /api/v1/countries.json.